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Abstract 
This thesis is a systematic literature review that will articulate the need for psychedelics as a 
treatment for several mental illnesses and ailments. Starting with the origins of psychedelics used 
in South American religious ceremonies and their development and early trials in the mid 20th 
century as well as the legal battles of psychedelics in American society. Additionally, this thesis 
examines the chemical structure, pharmacology, and safety of psychedelics. An in-depth 
examination of psychedelics as a therapy for treatment-resistant depression, depression and 
anxiety as a result of a cancer diagnosis, nicotine addiction and alcoholism, OCD, PTSD, and 
cluster headaches will be conducted as well as potential therapeutic uses for treating 
inflammation and the possibility of using psychedelics for tissue regeneration. Present-day 
studies that are currently in Phase 2 and Phase 3 of trials will also be explored including the 
contemporary challenges psychedelics face as becoming a part of modern society and their 
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 For some time now, some drugs that have been classified as illicit and illegal now are 
being studied for their potential therapeutic effects on the body and mind alike. The most well-
known illicit drug that has been researched for having positive effects on health is marijuana. 
Marijuana also provides a good model for drug legalization, in terms of research and 
controversy.  
 The most common use of marijuana is for the control of pain that is not caused by 
inflammation, such as chronic or neuropathic pain. It has also been used to help treat rare forms 
of epilepsy, used with chemotherapy, vomiting, nausea and weight loss from patients with 
HIV/AIDS. It can also be used in lieu of opiates to eliminate the chance of dependence on 
opiates. 
 The level of legality of marijuana varies from jurisdiction to jurisdiction. Marijuana is 
legal in some way, shape or form in 29 states as well as Washington D.C. but it still illegal at the 
federal level. People are still hesitant about legalizing it in full as there are still questions remain 
related to its safety or long-term effects. 
 Psychedelics are one of these drug classifications that could have potential positive health 
effects. Drugs in this class include classic hallucinogens such as lyseric acid diethylamide (LSD), 
methylenedioxymethamphetmaine (MDMA), psilocybin, and or N,N-Dimethyl-5-
methoxytryptamine (DMT). The main reason why the therapeutic use of psychedelics is being 
explored stems from the difficulty of treating several mental illnesses such an anxiety, 
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depression, obsessive compulsive disorder, post-traumatic stress disorder, alcoholism and 
nicotine addiction. At the moment, the standard course of treatment usually involves psycho-
therapy alone or in combination with selective serotonin-receptor inhibitors (SSRIs) or other 
antidepressants.  
 As with marijuana, the research and the therapeutic use of psychedelics has been 
challenging due to its legal status but it is currently experiencing important advances that might 
lead to its introduction in common medical practice in the near future. 
Methods 
 The articles found for this literature review were done systematically. This was done 
through OneSearch and keywords such as psychedelics, hallucinogens, LSD, mescaline, 
MDMA, DMT, psilocybin, psychedelic clinical use, history of psychedelics, PTSD psychedelics, 
depression psychedelics, OCD psychedelics, tissue regeneration psychedelics, cluster headaches 
psychedelics, substance abuse psychedelics, cancer patients psychedelics. The search settings 
were set to scholarly journal articles. This brought up 6,142 results. The articles, with the 
exception of the history of psychedelics, were set within the past 20 years which narrowed down 
the results to 1,531 hits. Of those 1,531 hits, the terms OCD, depression, anxiety, cluster 
headaches, substance abuse, cancer patients, inflammation, tissue regeneration where these 
keywords must be included in the articles with the keyword’s psychedelics, hallucinogens, LSD, 
mescaline, MDMA, DMT, psilocybin. This narrowed down the results to 217 hits. These articles 
were then examined individually through the abstracts to determine if there was sufficient data 
and results that could support the claims for psychedelic medicine, this narrowed down the 
results to 107 hits that are the basis of this literature review. 
History and Legality of Psychedelics  
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Psychedelics have been used for centuries by indigenous peoples with records of the 
earliest use of psychotropic plants dating back 5700 years used in Northeastern Mexico where 
they were used during religious ceremonies (Bruhn et al. 2002). It was formally introduced into 
Western society by Arthur Heffner in 1897 when he was able to isolate the compound mescaline 
from the peyote cactus and again in 1938 when chemist Albert Hoffman synthesized lysergic 
acid diethylamide (LSD) from ergot alkaloids. However, the hallucinogenic properties weren’t 
fully understood until 1943 when Hoffman accidentally ingested the 25th derivative of lysergic 
acid and experienced intense hallucinations. Hoffman also synthesized psilocybin in 1958 (J.D. 
Moreno 2016) (Rucker, lliff, and Nutt 2017) (Hoffman 2013) 
Psychedelics were an integral part of the counter-culture movement during the 1960s 
after LSD became popular by several authors including Timothy Leary. This led to the increased 
and often illegitimate use of psychedelics by sham psychiatrists, as well as “LSD parties” 
(Novak 1997). In 1957, the term “magic mushrooms” was coined by LIFE magazine (Wasson 
1957). At the beginning of the 1960s, Dr. Sidney Cohen began to question to safety of 
psychedelics, particularly LSD. He had previously taken a positive stance on psychedelic use, 
defending that if used properly, psychedelics could be very effective and helpful for people 
suffering from depression and anxiety alike. However, as the illicit use of psychedelics increased 
and a larger amount of the population began misusing the drug, he began to take a more cynical 
and bleak stance towards the subject (Novak 1997).  
Around this time, Congress tightened regulations for experimental drugs, including 
psychedelics, as a consequence of reports of severe birth defects in children whose mothers had 
taken thalidomide for morning sickness. In October of 1962, the FDA introduced Kefauver-
Harris Drug Amendments to limit the use of these experimental drugs. Following this 
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amendment, Sandoz stopped the production of LSD and psilocybin in 1965 (Stevens 1987). The 
use and regulation of magic mushrooms, LSD and mescaline were quite liberal until 1967 when 
the United Nations decided to classify all psychedelics as a Schedule I drug, effectively taking it 
off the shelves and making it nearly impossible to obtain. In 1968, Dr. Cohen helped to create the 
NIMH Division of Narcotics Addiction and Drug Abuse where he became the very first director. 
Around this time, the attitudes towards psychedelics turned increasingly sour as the so-called 
“war on drugs” initiative became mainstream and their effectiveness and safety were called into 
question ((Rucker, lliff, and Nutt 2017).  In 1970, President Richard Nixon passed the Controlled 
Substances Act effectively creating five schedules or drug levels based on therapeutic and abuse 
potential. LSD and psilocybin were placed in the most restrictive category, Schedule I, which 
requires special permits and licenses to obtain access to. (Lee, Johnson, and Griffiths 1992) In 
1981, the Common Rule was adopted making behavioral and biomedical research 
indistinguishable and as a result, the amount of research dwindled until the turn of the 21st 
century (J.D. Moreno 2016). 
However, this did not mean that research completely ceased. Instead, research was driven 
underground. Some people began to synthesize psychedelics for the main purpose of street sales 
while others wanted to find a similar hallucinogen that could be sold on the market, legally. Dr. 
Alexander Shulgin on the other hand, wanted to continue experimentation with psychedelics for 
therapeutic use. He first tried to experiment on animals with little success so he decided to 
experiment on himself. He was working for Dow Chemicals at that time and decided to leave the 
company to go back to school to learn more about chemistry. He eventually got a license to 
perform research with schedule I drugs. He published a book called PIHKAL (Phenethylamines I 
Have Known And Loved) which details his life and his study of psychedelics (Shulgin and 
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Shulgin 2002). This was the beginning of the end for Shulgin. After he published this book his 
relationship with the DEA quickly began to deteriorate and he began to be inspected more often 
and eventually he got his license revoked.  
 Beginning in the early 1990s, the interest in psychedelics was rejuvenated (Strassman 
1996). In 2006, several researchers published that people who had a psychedelic experience 
reported it being one of the top five most influential, meaningful and important experiences in 
their life - comparable with the birth of a child (RR Griffiths, Richards, and McCann 2006). 
Since then, the research on psychedelics has gradually returned.  
 
Chemical Structure of Psychedelics 
 Under the Controlled Substances Act, all psychedelics are classified as Schedule I drugs 
by the DEA. Drugs are classified as Schedule I when they have no current acceptable medical 
use, their safety is questionable, and they present the highest abuse potential.   
 Psilocybin (C12H17N2O4P), the active ingredient in magic mushrooms, otherwise 
known by its street name shrooms, is a tryptamine alkaloid which is a tertiary amino compound 
and an organic phosphate. Tryptamines are derived from the amino acid tryptophan and can be 
found in over 200 species of Basidiomycota mushrooms, where both the caps and stems contain 
active psilocybin. Psilocybin has a N,N-dimethyltryptamine carrying an additional 
phosphoryloxy substituent at the fourth position (Medicine and NIH).  
 Mescaline (C11H17NO3) is a phenethylamine alkaloid which is a member of the 
methoxybenzene family and a primary amino compound. Phenethylamines are organic 
compounds, natural monoamine alkaloid and trace amine. Mescaline is found in several cacti 
plants including the peyote cactus, the San Pedro cactus, and the Peruvian Torch cactus. In 
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mescaline, the phenethylamine is substituted at the third, fourth and fifth positions by methoxy 
groups (Medicine and NIH). 
 MDMA (C11H15NO2), or 3,4methylenedioxymethamphetmaine, otherwise known as 
molly or ecstasy is a ring-substituted amphetamine derivative in the same class as 
methamphetamine (meth) and structurally related to mescaline. MDMA was developed by a 
German pharmaceutical company in 1912. As a member of benzodioxoles, the 1,3-benzodioxole 
is substituted by a 2-methylamino propyl group at the fifth position (Medicine and NIH) 
 DMT (C13H18N2O), or N,N-Dimethyl-5-methoxytryptamine is a tryptamine alkaloid, an 
aromatic ether and a tertiary amino compound. substituted by a methoxy group at the fifth 
position and is derived from a bufotenin. DMT is found in several plant species such as 
ayahuasca and the Colorado River toad. It is used in South American religious and spiritual 
rituals as well (Medicine and NIH). 
 Lysergic acid diethylamide (C20H25N3O), otherwise known as acid is an ergoline 
alkaloid which is an organic heterotetracyclic compound and a monocarboxylic acid amide. 
Ergoline alkaloids are in fungi and some flowering plant species, including the Mexican species 
Turbina corymbose. Lysergic acid diethylamide is the result from the formation of lysergic acid 



































































Pharmacology of Psychedelics 
The majority of compounds within the psychedelic class of drugs function as non-
selective serotonin agonists with psychoactive effects primarily thought to be related to agonism 
of the 5-hydroxytryptamine 2A (5-HT2A) receptor subtype. The 5-HT2A receptor is a G protein-
coupled receptor (GPCR) that preferentially couples with a Gg-protein, stimulating the 
subsequent activation of phospholipase C and the signaling cascade that leads to the activation of 
protein kinase C and mobilization of Ca2+ from intracellular stores (Thomas, Malcolm, and 
Lastra 2017).  
The first experiment to illustrate this mechanisms in humans was a clinical study in 1998. 
It clearly showed that the hallucinogenic effects of psilocybin were blocked by the 5-HT2A 
receptor-selective antagonist ketanserin. With this data and observations, a direct correlation 
could be made that the experiences felt from psilocybin were due to the activation of the 5-HT2A 
receptor (Vollenweider et al. 1998). 
Unfortunately, that is the only definitive evidence in humans that is available as to what 
the actual mechanisms of psychedelics are in the human brain. All psychedelic drugs are 
chemically related but they are not identical in terms of their mechanisms of action. The 
pharmacology of each of these psychedelics are incredibly diverse and have a wide range of 
effects on the brain which can lead to a high risk of interactions with other drugs or conditions. 
We do not completely understand how psychedelics work which makes it difficult to understand 
the dose-response relationships, duration of action and toxicity of psychedelic medication. These 
must be known or at least have a basic understanding of them in order to ensure the efficacy and 
safety of psychedelics (Sellers and Leiderman 2017). 
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However, in the past ten to fifteen years, technology imaging technology has greatly 
improved so that it has allowed scientists to see the effects of psychedelics on the brain firsthand. 
These new technologies have revealed that brain activity is organized into functional networks, 
known as resting-state networks (RSNs). Scanning of these networks has allowed scientists to 
learn extensively about how psychiatric illnesses can disturb these delicate networks. These 
altered states coming from obsessive-compulsive disorder, depression, anxiety and many more 
illnesses can be detected by blood oxygen level-dependent fMRI. (Yuan et al. 2016). The 
greatest improvements in symptoms occur in patients who have a powerful, mystic, transcendent 
experience. (RR Griffiths et al. 2006). In a study, it was found that psilocybin decreased the 
connectivity within an important brain network called the default mode network (DMN). Using 
BOLD fMRI the researchers were able to observe decreased brain activity in the posterior 
cingulate cortex as well as in the medial prefrontal cortex, which are typically overactive in 
patients with major depression. (Robin L. Carhart-Harris et al. 2017). This is all exceptionally 
promising in the possibility of treating major depression. 
 
Safety of Psychedelics 
Research has shown that psychedelics are much more physiologically safe than opiates 
(Jaffe 1985). The peripheral activation of the 5-HT2A receptor is associated with increased 
vascular which can lead to thrombus formation, platelet aggregation and coronary artery spasms 
(Nagatomo et al. 2004). 5-HT2A receptors are also responsible for the constriction of the portal 
venous system. When taken in an uncontrolled environment, paranoia and distress can result 
from it. 
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Even when massive doses of LSD were consumed (1000-7000ug compared to the normal 
100-200ug dose), the individuals survived with hospital treatment without any known long term 
adverse effects. Despite the unpleasant symptoms of hyperthermia, respiratory problems or being 
in a comatose state, they could be saved (Klock, Boerner, and Becker 1974).  
Mescaline, still commonly used and legally allowed for use by Native American tribes 
and churches, has not been shown to cause neurological deficits. This was investigated by 
assessing cognitive function using the Rand Mental Health Inventory where no significant 
deficits were observed (Halpern et al. 2005).  
Regarding MDMA, there have been reports of increased feelings of anxiety, depressed 
mood and irritability, as well as more general feelings of dizziness, fatigue, headache, tight jaw, 
and nausea in over 40% of the participants which typically subsided over the next seven days. 
This was after active doses of MDMA ranging from 75-125 mg were administered in six 
randomized, double-blind, controlled clinical trials from April 2004 to February 2017. There 
were no changes in neurocognitive function observed, which means that the MDMA did not 
cause an neuro deficits and their cognitive level stayed the same. There were however, four 
reported cases of suicidal ideation but there was no suicidal behavior during the treatment period 
of dosing. (Mithoefer et al. 2019).  
When psilocybin is administered in a controlled setting, typically under the supervision 
of a qualified health professional, it can cause delayed headaches with differences of severity and 
incidence according to dosage (Johnson, Sewell, and Griffiths 2012). However, when psilocybin 
is ingested by a person with other medical conditions, it can have severe, harmful effects as 
illustrated by a hepatitis C-infected 25-year old man who developed rather severe 
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rhabdomyolysis, renal failure, encephalopathy and cortical blindness but was able to recover 
over several months back to full health (Bickel et al. 2005).  
The main adverse effects reported with the use of psychedelics is impaired judgement 
which is a major concern when used recreationally, or a heightened and altered sense of self, 
which have occasionally led to accidental deaths (i.e. by jumping off a building because the 
individual thought that they could fly).  (Keeler and Reifler 1967) 
 
Therapeutic Uses of Psychedelics 
 In recent years, there has been great speculation about the potential therapeutic effect of 
psychedelics for patients afflicted by a variety of mental illnesses. There was quite a bit of 
research done prior to the passing of the Controlled Substances Act of 1970. After this legislation 
passed and was put into effect, clinical research about this potential treatment option for mental 
conditions essentially ceased until the 2000s. (L. Grinspoon and Bakalar 1997). However, 
research with controlled substances remains challenging and few studies have been able to be 
conducted with appropriate sample size and study design until recently.  
Depression 
 Depression is a very prevalent and debilitating mental illness affecting over 17 million 
adults and almost 2 million children in the United States (Major Depression 2017) and is the 
leading cause of suicides and disability worldwide (WHO 2017). It affects women twice as much 
as men, including postpartum and major depression (Prevalence of Depression Among Adults 20 
and Over 2017).  
The current standard method to treat depression is to use cognitive behavioral therapy 
(CBT) alone or in conjunction with one or several antidepressant medications such as selective 
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serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), with around 50% of 
patients noticing an improvement in symptoms (Pharmacists) 2020). CBT therapy alone can be 
very effective for mild and situational depression but patients diagnosed with major depression 
are usually subjected to the trial-and-error method to find the right antidepressant. One 
antidepressant may improve the condition for one patient but can make another patient worse off 
or have no effect at all. Those who suffer from treatment-resistant depression sometimes have to 
resort to more aggressive forms of treatment such as electroconvulsive therapy (ECT) which is 
very effective but has many unwanted side effects and some argue that the risks outweigh the 
benefits (Kerner and Prudic 2014). These problems highlight the need for alternative, safer 
treatments. One of these options are psychedelics.  
Recently, there have been open-label studies of ayahuasca, an ancient compound used in 
religious ceremonies by the South American indigenous populations near the Amazon Basin. 
The compound sis extractedfrom the Psychotria viridis and Banisteriopsis cappi plants. It has 
been legal for spiritual practices in Brazil since 1987 (Frecska, Bokor, and Winkelman 2016).  
In 2015, ayahuasca was given in a single dose to 17 participants who were diagnosed 
with major depressive disorder. The severity of depression in these individuals was measured by 
two scales, the Hamilton Depression Rating scale (HAM-D) & the Montgomery-Aesberg 
Depression Rating Scale (MADRS) before and after the ayahuasca was administered. Within 
hours, study participants experienced a notable decrease in depressive symptoms which was 
maintained for up to three weeks (Osorio et al. 2015). Despite these hopeful outcomes, the 
relevance of these results is compromised by the sample size and the lack of a control group in 
the experimental design. 
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In 2019, another trial was done using the same depression measuring scales but this time 
a bit larger and using a placebo-controlled group. In this study, ayahuasca showed a significant 
improvement in depressive symptoms compared to placebo. This study confirmed the potential 
prospects of therapeutic effects on patients suffering from major depression (Palhano-Fontes et 
al. 2019). Furthermore, mental health evaluations done on regular ayahuasca consumers 
compared to non-ayahuasca consumers showed that regular ayahuasca consumers experienced a 
preserved cognitive state, reduction of anxiety, an increased sense of well-being, and less 
depressive symptoms ((Bouso et al. 2012),(Grob et al. 2011), (Barbosa et al. 2016). The main 
limitation of these studies often include sample size, and the examination of only treatment-
resistant depression. Another obstacle is trying to maintain complete double blindness 
throughout the entire trial as participants who have had ingested a psychedelic drug display very 
unique effects (Palhano-Fontes et al. 2019).  
Psilocybin is also another promising psychedelic to treat depression. A 2016 small-scale 
study on participants who had treatment resistant major depression using the HAM-D and BDI 
scale showed that by the end of the first week, the response rate to psilocybin was 67% and 
seven out of the eight patients went into remission. At 3 months, 58% of the participants 
continued to maintain their alleviated symptoms and 42% remained in remission. Once again 
these are promising results, but a blind, randomized study is still lacking (Robin L Carhart-
Harris, Bolstridge, et al. 2016).  
Another study was done with psilocybin in 2017 where functional magnetic resonance 
imaging (fMRI) was used to measure cerebral blood flow (CBF) and blood oxygen-level 
dependent (BOLD) resting-state functional connectivity (RSFC). fMRIs were done pre and post 
treatment with psilocybin. Within the first week, all 19 participants showed decreased depressive 
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symptoms and by week five, almost half of the participants maintained this reduction in 
symptoms. The fMRIs from patient’s post-treatment revealed a decrease in activity in the 
temporal cortex as well as in the amygdala which is correlated with decreased depressive 
symptoms. Increased RSFC was seen post treatment within the default-mode network (DMN). 
There was also an increased ventromedial prefrontal cortex-bilateral inferior lateral parietal 
cortex RSFC. The observations support the current theory is that psilocybin appears to have a 
“reset” effect on the brain, returning the state of the brain back to the equilibrium before the 
depressive symptoms began (Robin L. Carhart-Harris et al. 2017).  
Another fascinating aspect of psilocybin therapy is the reduction of suicides in people 
who have consumed it even if it was only once in their entire lifetime. Thoughts of suicide, 
suicide attempts, and psychological distress were all found to be decreased after psilocybin use 
and psilocybin has been suggested as a “suicide prophylaxis” (Hendricks, Johnson, and Griffiths 
2015).  
Depression and Anxiety in Terminal Patients 
Psychedelics have also been used to help ease the minds of patients who have gotten a 
life-altering or life-threatening diagnosis such as cancer. Depression affects 20% of cancer 
patients compared to around 6% in the general population. Traditional antidepressants can have 
negative interactions with chemotherapy medications and can worsen cancer symptoms like 
nausea, fatigue and weight-loss (Pitman et al. 2018).  Because of this, researchers have been 
looking into alternatives to aide patients in such situations.  
LSD was the very first psychedelic to be researched for this purpose in the 1960s. A 
group of researchers went to Spring Grove State Hospital in Maryland to conduct research on 
patients who were dying of cancer in 1963. Around two-thirds of the cancer patients treated with 
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LSD felt a sense of relief as well as an improved mood and reduced anxiety associated with the 
fear of death (Pahnke et al. 1970).  
A double-blind placebo-controlled study with psilocybin on this patient population was 
conducted in 2011 with twelve participants with advanced-stage cancer who were experiencing 
reactive anxiety and subsequent depression. A baseline score of anxiety and depression were 
measured by Beck Depression Inventory (BDI) and State-Trait Anxiety Inventory (STAI) before 
the psilocybin was administered as well as a Profile of Mood States (POMS). The participants 
were tracked for six months. The mean BDI score was lower than baseline after six months and 
the mean STAI was lower than baseline after only one month compared to the placebo. 
However, the mean POMS score was not significantly different than the baseline score taken 
before the administration of psilocybin (Grob et al. 2011).  
Research continued and in 2014 was done with LSD with twelve patients that were 
diagnosed with life-threatening diseases. The study found positive trends with a State-Trait 
Anxiety Inventory (STAI) over the course of twelve months (Gasser et al. 2014). This study has 
proven LSD-assisted therapy can be extremely beneficial to patients who are experiencing life-
threatening diseases.  
Another similar double-blind and placebo-controlled trial was conducted in 2016, but this 
time with twenty-nine participants using psilocybin and psychotherapy combined (or placebo 
and psychotherapy combined). The study found that in addition to the rapid anti-depressant 
effects psilocybin had on the participants and increase in quality of life, these effects were 
sustained for several months. By the six and a half month follow up, between 60-80% of the 
participants in the study were continuing to experience significant reductions in depression and 
anxiety as well as improved attitudes towards death and dying (Ross et al. 2016).  
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Also in 2016, another trial was conducted (randomized, double-blind, cross-over) with 
fifty-one cancer patients. The cancer patients’ immediate community (hospital staff workers such 
as nurses, therapists, doctors and family), rated the patient’s mood, behavior and attitudes 
throughout the study. At the six-month mark after the study had begun, over 80% of the patients 
showed continued and sustained improved mood and anxiety as well as reported increased well-
being and life satisfaction which matched the patient’s immediate community’s observations 
(R.R. Griffiths et al. 2016).  
These trials with psilocybin were small and not always uniform throughout, so Johns 
Hopkins and New York University tried to overcome the limitations of previous studies (sample 
size, lack of standardization) and designed a randomized double-blind and placebo controlled 
clinical trial which is the gold-standard to properly assess the efficacy of a pharmacological 
treatment. They also used differing doses of psilocybin and found that high doses of psilocybin 
(22 to 30 mg) had a distinct and significant advantage over low doses of psilocybin (1 to 3 mg). 
The participants who received the high doses of psilocybin experienced sustained reductions in 
depressive symptoms and anxiety as well as a feeling a greater sense of personal meaning in their 
lives (R Griffiths 2015).  
Substance Abuse and Nicotine Addiction Treatment 
 Alcohol use disorder affects nearly 15 million people in the United States over the age of 
12, with 9 million being men. Alcohol poisoning accounts for over 18% of emergency room 
visits with 95,000 individuals dying for alcohol-related death every year, and 10,000 of those 
deaths were from driving while under the influence. Alcoholism has been known as one of the 
leading causes of premature death and liver disease as well as heart disease and stroke. 
Alcoholics are also at an increased risk for depression and sleep disorders. Alcoholism is 
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typically treated with group therapy, individual psychotherapy or in combination with drugs such 
as acamprosate, disulfiram and naltrexone which have been shown to have varied success rates 
(Alcohol Use in the United States 2020).  
 Cigarette smoking is the leading cause of preventable deaths in United States with around 
435,000 people dying each year from smoking-related causes. Around 45 million Americans use 
tobacco products. Cigarettes can cause lung cancer, ulcers, infections, diabetes and reproductive 
disorders. Around 70% of smokers say that they want to quit smoking, but only 3% successfully 
quit (Benowitz 2010). 
Since both alcoholism and nicotine addiction are difficult to treat, psychedelics have been 
studied as a possible therapy. In the middle of the 20th century, LSD was being explored as an 
effective option to help people who were alcoholics, particularly by Canadian psychiatrists 
Humphrey Osmond and Abram Hoffer. In 1971, researchers looked at 1100 patients who 
suffered from alcoholism in the period from 1953-1969 who were treated with LSD. They came 
to the conclusion that at 10 months following the LSD treatment, 75% of patients experienced 
decreased use of alcohol compared to 44% of the control population (Abuzzahab and Anderson 
1971). While this data revelation was promising, research on psychedelics ceased for forty years 
until the 2010s due to tightened legislation. 
Psilocybin has also been effective in helping long-time cigarette users quit smoking. In 
2014, an open label study was conducted with fifteen participants who were nicotine-dependent 
cigarette smokers who wanted to quit smoking and had tried but failed. The study was a 15-week 
program combining CBT and psilocybin where CBT was done once a week and psilocybin 
administration took place at week 5, week 7 and an optional dose at week 13. At six months 
post-treatment, 80% (12 out of 15 participants) showed complete smoking cessation. This rate of 
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cessation is much higher than the average 35% other behavioral or drug therapies have to offer. 
Twelve months following this study, 67% of the participants maintained cessation of smoking 
(Garcia-Romeu, Griffiths, and Johnson 2014). 
Interestingly, psilocybin has also been used to help treat alcoholism, as shown in a study 
done in 2014 at the University of New Mexico. A sample group of ten volunteers with a clinical 
diagnosis of alcoholism were admitted to the study. The study first did cognitive behavior 
therapy (CBT), then CBT coupled with psilocybin administration, then a follow up post-
treatment. They found no decrease in alcohol abuse with just CBT alone, but found a dramatic 
decrease after the participants had received a dose of psilocybin. From these results they 
concluded that the more mystical the psilocybin experience, the stronger the improvement of 
behavior (Bogenschutz et al. 2014). 
 A meta-analysis revealed that a single dose of LSD administered to patients diagnosed 
with alcoholism showed a large decrease in the abuse of alcohol, coming to the conclusion that 
administration of LSD correlated with lower alcohol abuse. This analysis looked at 536 
participants, 325 who received the single dose or 211 who received the control, from the years 
1943 to 2010 (T. S. Krebs and Johansen 2012).    
Obsessive Compulsive Disorder  
 Obsessive Compulsive Disorder (OCD) is one of the most difficult mental illnesses to 
treat. Around 2.2 million Americans each year suffer from OCD each year, with over half of 
clinically diagnosed patients reporting severe impairment in daily life (NIMH 2019). OCD also 
has an incredibly high comorbidity rate with over 75% of patients with OCD having also been 
diagnosed with anxiety disorders such as panic attacks, phobias or PTSD; over 60% have been 
diagnosed with major depression or bipolar depression; 55% have been diagnosed with ADHD 
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and almost 40% have a substance abuse disorder (Psychiatry 2008).  Typical treatment of 
serotonin reuptake inhibitors (SSRIs) has limited efficacy with improvement in roughly half of 
patients which has allowed the opportunity for new therapies to arise. 
A case study with LSD done in 1977 was conducted on a thirty-year old man suffering 
from disabling OCD that prevented him from engaging in everyday activities. The treatment of 
this man was done over fifteen months solely with LSD. He was administered LSD at home and 
checked on by nurses and doctors over these fifteen months. At the three year mark, the man was 
completely symptom-free and continued to be symptom-free twelve years later (Brandrup and 
Vanggaard 1977).  
 Psilocybin has also been used to help treat OCD. In 1996, a twenty-seven-year old man 
with severe body dysmorphia who would spend hours looking in the mirror to inspect his 
appearance was given psilocybin mushrooms. After ingestion, his sense of body dysmorphia 
decreased and sense of well-being increased (Hanes 1996).  
 A pilot study of nine participants was done in 2006 with individuals clinically diagnosed 
with OCD. The participants were given four different doses of psilocybin, separated by one 
week. Their symptoms were measured at hours 4, 8, and 24 using the Yale-Brown Obsessive 
Compulsive Scale. Significant decreases in symptoms were observed in all participants with 
between a 23-100% reduction in symptoms. However, by the six month mark, only one 
participant was still in remission. Researchers suggest that this warrants future studies but instead 
with a blinded, randomized, placebo-controlled study for optimal results and data collection 
(F.A. Moreno et al. 2006).  
 While these short-term and small-scale studies provide promising results for those 
suffering from OCD, there is still need for extensive clinical trials in the future as current 
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treatments for OCD have less than ideal efficacy and LSD and psilocybin could hold a much-
needed treatment to those who are suffering from it. 
Post-Traumatic Stress Disorder  
 Post-traumatic stress disorder (PTSD) is a common illness seen in combat veterans who 
have witnessed death or experienced severe injury themselves but it also common in survivors of 
sexual assault, rape or domestic abuse. Around 8 million adults in the United States have had 
PTSD in the past year. The standard course of treatment is typically CBT alone or used in 
conjunction with anti-depressants but that doesn’t always work for everyone (2019).  
 MDMA has been shown to help alleviate symptoms in those suffering from PTSD. 
MDMA significantly increases serotonin and dopamine levels which can elevate mood and 
improve behavior. The first study to look at the effect of MDMA-assisted psychotherapy on 
individuals experiencing PTSD was done in 2011 and this study found a dramatic decrease in 
symptoms; 83% of participants that received the MDMA dose during psychotherapy sessions 
experienced a decrease in symptoms compared to only 25% in the placebo + psychotherapy 
group (Mithoefer et al. 2011). This improvement was sustained 74 months after treatment in the 
majority of participants (Mithoefer et al. 2013).  
 A meta-analysis exploring the effects of MDMA on PTSD patients analyzed six different 
double-blind, controlled clinical trials at five separate study sites conducted between 2004 and 
2017. It was found that 54.2% of the participants who received the active MDMA dose 
experienced a decrease in symptoms while only 22.6% of participants in the control group 




 While cluster headaches are very rare, affecting up to 0.1% of the population, they are 
extremely painful, uncomfortable and severely debilitating. Individuals with cluster headaches 
can experience these painful attacks lasting from 15 to 180 minutes a day up to 8 times a day. 
The standard course of treatment is usually high-flow oxygen inhalation therapy but this usually 
requires a visit to a doctor’s office (Yi-Ting Wei, Jia Yuan Ong, and James Goadsby 2018).  
 In 2006, an online survey was conducted with 53 individuals who suffered from severe 
cluster headaches and found that 22 out of 26 individuals who used psilocybin found that it 
prevented the headaches from occurring while 25 out of 48 psilocybin users and 7 out of 8 LSD 
users found that the cluster headaches terminated. There was also a successful rate of remission 
of headache attacks for 18 of 19 psilocybin users and 4 of 5 LSD users (Sewell, Halpern, and 
Pope 2006).  
 There have also been reports of a non-hallucinogenic LSD derivative known as BOL-
148, to be effective in treating cluster headaches as well. This specific derivative was given to 
five individuals experiencing repeated cluster headache attacks and with a single oral dose of 
BOL-148, the severity of the cluster headache was severely reduced or the vicious cluster 
headache section was broken. This indicates that the therapeutic effect for the reduction in 
headache symptoms does not have to do with the psychoactive effects of the hallucinogenic 
version of LSD. The research on why this occurs is limited but theories have stated that these 
headaches are eased through the 5-HT2A receptor. The differences in pharmacology have been 




Other Potential Therapeutic Uses 
Inflammation  
 Most treatments for inflammation are put into three categories: nonsteroidal anti-
inflammatory drugs (NSAIDs), immunosuppressant steroid drugs (glucocorticoids), and 
biologics. NSAIDs work by blocking the activity of cyclooxygenases which produces 
prostaglandins to signal an inflammatory response. NSAIDs can be exceptionally hard on the 
kidneys and liver, especially to those that suffer from kidney or liver disease. Glucocorticoids, 
such as prednisone modify gene expression to prevent cytokine production, among other effects. 
Because these drugs suppress the immune system, individuals who take the medication are more 
susceptible to infection. Biologics are antibodies or antibody-like molecules which block the 
activity proinflammatory cytokines. Biologics can also cause an increased risk of infection as 
they control the inflammatory disease which can alter the immune system’s ability to fight 
infections. This has created the need for more therapies to treat and control inflammation that 
have less severe side effects. 
However, there appears to be a fourth class of anti-inflammatories: activators of the 
serotonin 5-HT2A receptor. Scientists have known for ages that increased serotonin correlated 
with an increase in serotonin receptors in inflamed tissues (Baganz and Blakely 2013). The 5-
HT2A receptor is the most widely expressed serotonin receptor in mammals, having a presence 
in essentially all tissues. A study on rats found that the activation of 5-HT2A receptor had an 
anti-inflammatory effect as it prevented the anti-inflammatory response induced by the tumor 
necrosis factor alpha (TNF-alpha) (Yu et al. 2008).  
While this research is very promising, there haven’t been any human trials examining 
this. The only current trials have been done on animals, primarily rats. The mechanism for the 
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anti-inflammatory properties to take place are still largely unknown and can only be 
hypothesized for the moment.  
 
Tissue Regeneration 
 Tissue regeneration is a very important field of medicine. The goal of tissue regeneration 
is to restore the function of tissue. This can help a variety of people who suffer from spinal cord 
injuries, liver or kidney disease, burn survivors, etc. The current experiments that have been done 
with tissue regeneration have been with pluripotent stem cells which can differentiate into 
different tissue types. According to recent research, psychedelics may have a role in regenerating 
tissue. 
 A study was conducted in 2006 on rats who received a staggered double hemi-section 
(DH) two days after they were born (P2) on the left hemi-cord at T11 and right hemi-cord at 
T12. Another group had a complete transection done at T11 (CT) and the last group was the 
control for the experiment. The rats were then treated with neurothrophin-2 (NT-3) and/or LSD. 
The drugs were administered just above the lesion site at post-natal days 4,6,8, and 10. The rats 
with the staggered double hemi-section and complete transection who received the NT-3 and 
LSD showed improved coordination and more kicks while swimming. By day 40, the kicking 
frequency was on par with the control group which suggests that NT-3 and LSD as a 
combination treatment might be an effective avenue for spinal cord injuries in humans as it 





Where Are We Now With Psychedelics? – Progress and Challenges  
 The current and main challenge with approving psychedelics for medical use is due to its 
classification as a Schedule I drug. For a Schedule I drug to be allowed for medical use requires 
several special licenses. To receive such special licenses, several security protocols must be in 
place to ensure it is only being used by approved individuals, who have had a background check, 
in the right context and environment. The trials with such drugs are closely monitored as well 
(Rucker, lliff, and Nutt 2017).  
 To bypass what could be a long and tedious process, the FDA has made available several 
special regulatory pathways. There is the Fast-track designation applies to a drug that is being 
intended to treat a serious condition and preliminary data points to a potential solution. There is 
the breakthrough therapy designation where the drug is intended to treat a serious condition and 
preliminary clinical evidence supports significant improvements in the subject’s condition. 
Another possibility is the accelerated approval pathway where the drug treats a serious condition 
and could potentially provide an advantage over current available therapies and possibly replace 
them as the leading way to treat that particular illness (Sellers and Leiderman 2017).  
  In 2019, the Food and Drug Administration (FDA), approved the beginning of Phase 3 
clinical trials with MDMA for severe PTSD. These Phase 3 trials are going to be large, multi-
center, and placebo-controlled for best possible results. These Phase 3 trials will be conducted at 
fifteen sites in the United States, Canada and Israel, with plans for expansion into the European 
Union. MDMA-assisted psychotherapy for the treatment of PTSD is anticipated to be approved 
by the FDA by the end of 2021 or the beginning of 2022 (Doblin et al. 2019).  
 Successful preliminary trials have led the FDA to approve two clinical trials for 
psilocybin in its treatment for depression. This process started in 2018 when the FDA proclaimed 
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Compass Pathways’ psilocybin research a major breakthrough and moved on the clinical trials to 
Phase 2B which are currently underway in both Europe and North America respectively. By the 
end of 2019, the breakthrough therapy status was also designated to the Usona Institute for its 
Phase 2 clinical trial and is expected to be finished in late 2021 (Covas and Campbell 2021).  
 Ayahuasca has been approved for Phase I trials for the formulation of ayahuasca tea from 
the two plants B. Caapi and P. viridis. As of early 2021, DMT, the active ingredient in 
ayahuasca, has been moved to a Phase I trial initiated by a London-based pharmaceutical 
company for treatment in patients suffering from anxiety and depression. A Dublin-based 
pharmaceutical company has announced its successful completion of their Phase I clinical trial 
with DMT and will begin Phase 2 soon (Zipkin 2021).  
 In 2020, a New York-based company acquired rights to begin eight clinical trials with 
LSD after preclinical research indicated potential efficacy for treating those with anxiety and 
ADHD. While this is a very important and promising step, the timeline for completion and 
approval is still relatively unclear (Williams 2020). 
Conclusion 
 While all of these trials have revealed some very important and ground-breaking 
information, psychedelics are still a long way from becoming a mainstream treatment for several 
illnesses and ailments. Psychedelics are unique in that they must be used under the direct 
supervision of a physician, so it’s called psychedelic-assisted therapy. Anti-depressants are 
prescribed and monitored by a physician in an indirect way in that you pick up the medication at 
a pharmacy and take it at home under the direction of a physician. Phase 3 and Phase 2 trials 
have just recently begun with different psychedelic drugs. Most other trials that have been done 
have been small-scale and poorly designed due to the legal aspects surrounding the acquisition of 
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such controlled substances. The recent designation of breakthrough therapy by the FDA for 
MDMA and psilocybin for PTSD and MDD, respectively, created an unprecedented opportunity 
for quality research that will provide much needed information to support the therapeutic use of 
psychedelics. 
 Another challenging obstacle is going to be changing the attitudes towards psychedelics. 
At the moment, psychedelics are clumped together with other illicit drugs such as cocaine and 
methamphetamine which are legitimately dangerous and pose severe health and societal 
concerns. Because of this, public opinion might associate psychedelics with dangerous drugs, 
even if they have widely different therapeutic and safety profiles. Public health initiatives from 
the National Institute of Health (NIH) and DEA are vital in changing this view. Without the 
support and trust from the general public, getting the approval of society and eliminating the 
taboo of psychedelics will make it hard for them to be integrated into society as a reliable form 
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